NCT00754351已完成2 期
Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer
University Hospital of Crete2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Overall response rate
研究概览
简要总结
This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab combination, administered biweekly, as salvage treatment in patients with metastatic and HER2 negative breast cancer.
详细描述
Docetaxel plus gemcitabine is an active combination in the salvage treatment for metastatic breast cancer. Administered every two weeks, this combination has a favorable toxicity profile, and promising activity in > 1st line treatment for metastatic breast cancer. Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone. This study will evaluate the addition of bevacizumab to a biweekly regimen of docetaxel and gemcitabine in the salvage therapy for metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically- or cytologically- confirmed metastatic breast adenocarcinoma
- •No HER2 overexpression or gene amplification
- •At least one previous chemotherapy regimen for metastatic breast cancer
- •Age ≥18 years
- •Performance status (WHO) 0-2
- •Life expectancy of at least 12 weeks
- •Measurable disease as defined by at least 1 bidimensionally measurable lesion ≥ 20 X 10 mm
- •Performance status (WHO) 0-2
- •Adequate liver function (serum bilirubin <1.5 times the upper normal limit, AST and ALT <2.5 times the upper normal limit in the absence of demonstrable liver metastases, or <5 times the upper normal limit in the presence of liver metastases), adequate renal function (serum creatinine <1.5 times the upper normal limit) and bone marrow ≥ 1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 9 g/dL) function
- •Written informed consent
排除标准
- •Pregnant or lactating women
- •Progressive brain metastases according to clinical or radiological criteria
- •Brain metastases without prior radiation therapy
- •Radiation therapy within the previous 4 weeks
- •Previous radiation therapy to the only measurable lesion
- •Proteinuria ≥ 500 mgr of protein daily
- •Uncontrolled hypertension
- •Documented hemorrhagic diathesis or coagulation disorder
- •Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF < normal, ventricular arrhythmia, uncontrolled hypertension)
- •Thrombotic event within the previous 6 months
- •Concurrent use of aspirin > 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents
- •Major surgical procedure within the previous 4 weeks
- •Presence of nonhealing wound or fracture
- •Peripheral neuropathy > grade 2 according to the NCI CTCAE (version 3.0)
- •Any sustained chronic toxicity > grade 2 according to the NCI CTCAE (version 3.0)
- •Uncontrolled infection
- •Any serious, uncontrolled comorbidity on the investigator's judgment
- •Other cancer within the previous 5 years, except non-melanoma skin cancer and in situ cervical cancer
- •Serious psychiatric illness
研究组 & 干预措施
1
Experimental
Bevacizumab->Docetaxel->Gemcitabine
干预措施: Bevacizumab (Drug)
1
Experimental
Bevacizumab->Docetaxel->Gemcitabine
干预措施: Docetaxel (Drug)
1
Experimental
Bevacizumab->Docetaxel->Gemcitabine
干预措施: Gemcitabine (Drug)
结局指标
主要结局
Overall response rate
时间窗: up to 6 months
次要结局
- Progression Free Survival(1 year)
- Toxicity profile(21 days)
- Overall Survival(1 year)
- Quality of life assessment(Assessment every two cycles)
研究者
Vassilis Georgoulias, MD
Prof. D. Mavroudis
University Hospital of Crete
研究点 (2)
Loading locations...
相似试验
终止
3 期
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine LeiomyosarcomaRecurrent Uterine Corpus SarcomaStage IIIA Uterine SarcomaStage IIIB Uterine SarcomaStage IIIC Uterine SarcomaStage IVA Uterine SarcomaStage IVB Uterine SarcomaUterine Corpus LeiomyosarcomaNCT01012297National Cancer Institute (NCI)107
已完成
1 期
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast CancerBreast CancerNCT00705315Hellenic Oncology Research Group46
已完成
2 期
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney FunctionDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder CancerNCT00478361M.D. Anderson Cancer Center40
终止
3 期
Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLCNon-small-cell Lung CancerNCT00442026Hellenic Oncology Research Group106
终止
1 期
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)Malignant Peripheral Nerve Sheath TumorMalignant FibrousHistiocytoma/Undifferentiated Pleomorphic SarcomaLeiomyosarcomaSarcomaNCT01418001Memorial Sloan Kettering Cancer Center5